The FDA on May 11th updated its final guidance on “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency” to address new questions, including the use of alternate laboratory or imaging centers, video conferencing and postmarketing requirements. The update also features clarifications to questions addressed in previous versions of the guidance on managing protocol deviations and amendments and on steps sponsors should take when considering administering investigational products at home instead of at clinical trial sites.